Systemic and immune manifestations in myelodysplasia: A multicenter retrospective study

Ana de Hollanda(Université d'Angers), C. Belizna(Centre National de la Recherche Scientifique), Norbert Ifrah(Inserm), H. Lévesque(Université de Rouen Normandie), M. Hamidou(Centre Hospitalier Universitaire de Nantes), Christian Lavigne(Université d'Angers), J.F. Subra(Centre Hospitalier Universitaire d'Angers), A. Beucher(Université d'Angers), Daniel Henrion(Centre National de la Recherche Scientifique), A. Ghali(Laboratoires d'Anjou (France))
Arthritis Care & Research
May 16, 2011
10.1002/acr.20504
Cited by 97

Related Papers

Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing
|Clinical Pharmacology & Therapeutics|2010|363
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
|Blood|2013|357
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia
|Blood|2013|286
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways
|Blood|2007|252
The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation
|Blood|2010|196